Doubts over "metabolic syndrome" weigh on Sanofi (Reuters)


Reuters - The world's top two diabetes
organizations have questioned the existence of a medical
condition widely cited by drug firms, in a move that could
hamper prospects for Sanofi-Aventis's new drug Acomplia.

Read more...